References
- Seguí MA , Crespo C , Cortés J , et al. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective. Expert Rev Pharmacoecon Outcomes Res 2014;14(6):889-99
- Denduluri N , Rugo HS , Davis SE , et al. Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts). J Clin Oncol 2011;29(Suppl 27; Abstract 13
- Poulet B , Jamshidian F , Butler S , et al. Risk classification of early stage breast cancer as assessed by MammaPrint and Oncotype DX genomic assays. 2012 San Antonio Breast Cancer Symposium. Abstract #P6-07-03
- Shivers SC , Clark L , Esposito N , et al. Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer. 2013 San Antonio Breast Cancer Symposium; Abstract #P6-07-03
- Paik S , Tang G , Shak S , et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34
- Albain KS , Barlow WE , Shak S , et al. Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer. Lancet Oncol 2010;11(1):55-65
- Knauer M , Mook S , Rutgers EJ , et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120(3):655-61
- Estevez LG , Calvo I , Abad MF , et al. A retrospective study in the Spanish population with Oncotype DX recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes. 2013 ASCO Annual Meeting; Abstract No. e11531
- Caro JJ , Briggs AH , Siebert U , Kuntz KM . ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health 2012;15(6):796-803